Related Experiment Video
Updated: Feb 17, 2026

Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells
Published on: January 6, 2014
Cancer Stem Cell-Suppressing Activity of Chrysotoxine, a Bibenzyl from Dendrobium pulchellum
Narumol Bhummaphan1, Varisa Pongrakhananon1, Boonchoo Sritularak1
1Inter-Department Program of Biomedical Sciences, Faculty of Graduate School, Department of Pharmacognosy and Pharmaceutical Botany; Faculty of Pharmaceutical Sciences, Department of Pharmacology and Physiology; and Cell-Based Drug and Health Product Development Research Unit, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Pathumwan, Bangkok, Thailand.
Abstract:
Cancer stem cells (CSCs) have been recognized as rare populations driving cancer progression, metastasis, and drug resistance in leading cancers. Attempts have been made toward identifying compounds that specifically target these CSCs. Therefore, investigations of novel therapeutic strategies for CSC targeting are required. The cytotoxic effects of chrysotoxine on human non-small cell lung cancer-derived H460 and H23 cells were evaluated by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. The effects of chrysotoxine suppression of CSC-like phenotypes were determined in CSC-rich populations and primary CSCs in three-dimensional (3D) culture and in an extreme limiting dilution assay. Expression of CSC markers and associated proteins was determined by Western blot analyse and flow cytometry. We have reported herein the CSC-suppressing activity of chrysotoxine, a bibenzyl compound isolated from Dendrobium pulchellum We have shown, to our knowledge for the first time, that chrysotoxine dramatically suppresses CSC-like phenotypes of H460 and H23 cells. Treatment with chrysotoxine significantly reduced the viability of 3D CSC-rich populations and concomitantly decreased known CSC markers. Chrysotoxine suppressed CSC phenotypes through downregulation of Src/protein kinase B (Akt) signaling. Active (phosphorylated Y416) Src was shown to regulate cancer stemness, since ectopic overexpression of Src strongly activated Akt and subsequently enhanced pluripotency transcription factor SRY (sex-determining region Y)-box 2 (Sox2)- mediating CSC phenotypes, whereas the short hairpin RNA of Src and an Src inhibitor (dasatinib) suppressed Akt, Sox2, and CSC properties. Importantly, chrysotoxine was shown to suppress active Src/Akt signaling and in turn depleted Sox2-mediated CSCs. Our findings indicate a novel CSC-targeted role of chrysotoxine and its regulation by Src/Akt and Sox2, which may be exploited for cancer treatment.
Insights
Chrysotoxine, a natural compound, effectively suppresses cancer stem cell phenotypes in lung cancer by inhibiting the Src/Akt/Sox2 signaling pathway, offering a potential new cancer treatment strategy.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Cancer stem cells (CSCs) drive tumor progression, metastasis, and treatment resistance.
- Targeting CSCs is crucial for developing effective cancer therapies.
- Novel therapeutic strategies for CSC targeting are urgently needed.
Purpose of the Study:
- To investigate the CSC-suppressing activity of chrysotoxine, a bibenzyl compound from *Dendrobium pulchellum*.
- To elucidate the molecular mechanisms underlying chrysotoxine's effects on CSCs.
- To evaluate chrysotoxine as a potential therapeutic agent for lung cancer.
Main Methods:
- Cytotoxicity assays (MTT) on H460 and H23 lung cancer cells.
- Assessment of CSC-like phenotypes in 3D cultures and extreme limiting dilution assays.
- Western blot and flow cytometry to analyze CSC markers and signaling proteins (Src, Akt, Sox2).
Main Results:
- Chrysotoxine significantly reduced the viability of CSC-rich populations and suppressed CSC markers.
- Chrysotoxine downregulated the Src/protein kinase B (Akt) signaling pathway.
- Chrysotoxine inhibited Sox2 expression, a key mediator of CSC phenotypes, by suppressing active Src/Akt signaling.
Conclusions:
- Chrysotoxine exhibits potent CSC-suppressing activity in non-small cell lung cancer.
- Chrysotoxine targets CSCs by downregulating the Src/Akt/Sox2 signaling axis.
- Chrysotoxine represents a promising novel therapeutic candidate for cancer treatment.
More Related Videos
06:00Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
Published on: May 14, 2016
13:38Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells
Published on: January 18, 2017
Related Concept Videos
Cancer Stem Cells and Tumor Maintenance
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Drugs that Stabilize Microtubules
Drugs that Destabilize Microtubules
Targeted Cancer Therapies
There are several types of targeted therapies against...
Distinctive Features of Adult Stem Cells vs Cancer Stem Cells
Adult stem cells
Adult stem cells are tissue-specific; hence, they divide to develop the tissue from which they originate. One type of adult stem cell is the epithelial stem cell, which gives rise to the keratinocytes in the multiple layers of epithelial cells in the epidermis of the skin. Adult bone marrow has three distinct types of stem cells:...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...